Coronary thrombus composition: Links with inflammation, platelet and endothelial markers

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 555-561

  Sadowski, Marcin ^a   Zabczyk, Michał ^b,c   Undas, Anetta ^b,c  

^a Swietokrzyskie Cardiology Centre   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Endothelial activation; Fibrin clot; Inflammation; Platelet; ST Segment elevation myocardial infarction; Thrombosis; Thrombus

Indexed keywords

ABCIXIMAB; BIOLOGICAL MARKER; CD40 LIGAND; FIBRIN; FIBRINOGEN; MYELOPEROXIDASE; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

AGED; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR INFLAMMATION; CATHETER; CELL ACTIVATION; CELL COMPONENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CORONARY ARTERY THROMBOSIS; END STAGE RENAL DISEASE; EPITHELIUM CELL; EUGLOBULIN LYSIS TEST; EX VIVO STUDY; FEMALE; FIBRINOLYSIS; HUMAN; HYPERTENSION; LEUKOCYTE ACTIVATION; MALE; PERCUTANEOUS CORONARY INTERVENTION; SCANNING ELECTRON MICROSCOPY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; THROMBECTOMY; THROMBOCYTE ACTIVATION; THROMBUS ASPIRATION; VASCULAR ENDOTHELIUM;

EID: 84908565837     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.020     Document Type: Article

References (30)

1. Undas A., Ariëns R.A. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 2011, 31:e88-99.
2. Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol. Arch. Med. Wewn. 2011, 121:310-319.
3. Collet J.P., Allali Y., Lesty C., et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2567-2573.
4. Undas A., Szuldrzynski K., Stepien E., et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008, 196:551-557.
5. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003, 108:1664-1672.
6. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg P.G., James S.K., Atar D., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 2012, 33:2569-2619.
7. Kumbhani D.J., Bavry A.A., Desai M.Y., et al. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J.Am. Coll. Cardiol. 2013, 62:1409-1418.
8. Silvain J., Collet J.P., Nagaswami C., et al. Composition of coronary thrombus in acute myocardial infarction. J.Am. Coll. Cardiol. 2011, 57:1359-1367.
9. Yunoki K., Naruko T., Sugioka K., et al. Thrombus aspiration therapy and coronary thrombus components in patients with acute ST-elevation myocardial infarction. J.Atheroscler. Thromb. 2013, 20:524-537.
10. Uchida Y., Uchida Y., Sakurai T., et al. Characterization of coronary fibrin thrombus in patients with acute coronary syndrome using dye-staining angioscopy. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1452-1460.
11. Barba I., Garcia del Blanco B., Abdul-Jawad O., et al. MRI discriminates thrombus composition and ST resolution after percutaneous coronary intervention in patients with ST elevation myocardial infarction. PLoS One 2011, 6:e18459.
12. Sato Y., Hatakeyama K., Yamashita A., et al. Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. Heart 2005, 91:526-530.
13. Ferrante G., Nakano M., Prati F., et al. High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation 2010, 122:2505-2513.
14. Yunoki K., Naruko T., Sugioka K., et al. Erythrocyte-rich thrombus aspirated from patients with ST-elevation myocardial infarction: association with oxidative stress and its impact on myocardial reperfusion. Eur. Heart J. 2012, 33:1480-1490.
15. Undas A., Podolec P., Zawilska K., et al. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke 2009, 40:1499-1501.
16. Blombäck M., He S., Bark N., et al. Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate. Br. J. Haematol. 2011, 152:758-765.
17. Guimarães A.H., de Bruijne E.L., Lisman T., et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br. J. Haematol. 2009, 145:115-120.
18. van't Hof A.W., Liem A., Suryapranata H., et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998, 97:2302-2306.
19. Undas A., Wiek I., Stȩpień E., et al. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. Diabetes Care 2008, 31:1590-1595.
20. Undas A., Nycz K., Pastuszczak M., et al. The effect of chronic kidney disease on fibrin clot properties in patients with acute coronary syndrome. Blood Coagul. Fibrinolysis 2010, 21:522-527.
21. Rajzer M., Wojciechowska W., Kawecka-Jaszcz K., et al. Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication. Thromb. Res. 2012, 130:99-103.
22. Undas A., Szułdrzyński K., Brummel-Ziedins K.E., Tracz W., Zmudka K., Mann K.G. Systemic blood coagulation activation in acute coronary syndromes. Blood 2009, 113:2070-2078.
23. Blann A.D., Nadar S.K., Lip G.Y. The adhesion molecule P-selectin and cardiovascular disease. Eur. Heart J. 2003, 24:2166-2179.
24. Amelot A.A., Tagzirt M., Ducouvret G., et al. Platelet factor 4 (CXCL4) seals blood clots by altering the structure of fibrin. J.Biol. Chem. 2007, 282:710-720.
25. Mutch N.J., Engel R., Uitte de Willige S., et al. Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 2010, 115:3980-3988.
26. Antoniades C., Bakogiannis C., Tousoulis D., et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J.Am. Coll. Cardiol. 2009, 54:669-677.
27. Yacoub D., Hachem A., Théorêt J.F., et al. Enhanced levels of soluble CD40 ligand exacerbate platelet aggregation and thrombus formation through a CD40-dependent tumor necrosis factor receptor-associated factor-2/Rac1/p38 mitogen-activated protein kinase signaling pathway. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2424-2433.
28. Spiel A.O., Gilbert J.C., Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008, 117:1449-1459.
29. Rebeiz A.G., Tamim H.M., Sleiman R.M., et al. Plasma myeloperoxidase concentration predicts the presence and severity of coronary disease in patients with chest pain and negative troponin-T. Coron. Artery Dis. 2011, 22:553-558.
30. Sugiyama S., Kugiyama K., Aikawa M., et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1309-1314.